Latest news

Knight Partners with Debiopharm for the Commercialization of Trelstar® in Canada

Grand gagnant du Challenge 2019 pour la qualité de vie du patient, le projet Rise-Up de chaise élévatrice qui aide…

Après-demain Holding SA acquiert une participation dans le réseau de crèches Little Green House (Suisse)

Debiopharm progresses in their stand against drug-resistant N. gonorrhoeae with extended CARB-X funding of their Debio 1453 antibiotic program

A pancreatic and colorectal cancer trial initiated to address the needs of patients with Immune Checkpoint Inhibitor (ICI)-resistant disease by…

Debiopharm’s novel IAP antagonist Debio 1143 achieves outstanding Phase II results for high-risk Head and Neck cancer patients

The Japanese Cancer Association and Debiopharm Announce Winners of the 2019 JCA-Mauvernay Award

Debiopharm successfully completes randomized Phase II study for IAP antagonist Debio 1143 in high risk head & neck cancer patients

Debiopharm and BIOASTER join forces to expand research to combat infectious diseases